Johnson & Johnson unveiled its oncology strategy at the JPM26 event. Oncology will play a major role in the company's revenue outlook and is expected to generate up to $50 billion in sales by 2030.[4] The firm focuses on six priority areas, including oncology, immunology, neuroscience, cardiovascular medicine, surgery and vision care.[1][2] As part of the strategy, it plans to spin off the orthopedic division into a separate company, DePuy Synthes, within 18 to 24 months.[1] J&J acquired Halda Therapeutics for $3.05 billion, strengthening its portfolio in the treatment of solid tumors, including prostate cancer.[2][3][6] Halda's main drug is in early to mid-stage development, and the company has experimental procedures for breast, lung and other types of tumors.[3][6] These steps are intended to support growth after 2025 in connection with the expiring patent protection of key medicines.[2][6] Existing blood cancer drug Darzalex also made a strong contribution, with sales of $3.67 billion.[1]